6-Fluoromevalonolactone is a synthetic analog of mevalonolactone, a key intermediate in the biosynthesis of cholesterol and other isoprenoids. It acts as a potent inhibitor of hydroxymethylglutaryl-CoA reductase (HMG-CoA reductase), the rate-limiting enzyme in cholesterol biosynthesis. Due to its ability to block cholesterol synthesis, 6-fluoromevalonolactone has been investigated as a potential therapeutic agent for hypercholesterolemia and other cardiovascular diseases. The compound has also been studied for its potential anti-inflammatory and anti-cancer properties. Synthesis of 6-fluoromevalonolactone typically involves fluorination of mevalonolactone or a suitable precursor. The compound is often used in research to study the regulation of cholesterol biosynthesis and the effects of HMG-CoA reductase inhibition.'
```
ID Source | ID |
---|---|
PubMed CID | 119214 |
CHEMBL ID | 3185156 |
CHEBI ID | 125368 |
MeSH ID | M0131500 |
Synonym |
---|
4-(fluoromethyl)tetrahydro-4-hydroxy-2h-pyran-2-one |
6-fluoromevalonate, >=90% (gc), viscous liquid |
NCGC00165794-01 |
fluoromevalonate |
CHEBI:125368 |
2822-77-7 |
4-(fluoromethyl)-4-hydroxyoxan-2-one |
AKOS006285000 |
2h-pyran-2-one, 4-(fluoromethyl)tetrahydro-4-hydroxy- |
6-fmva |
6-fluoromevalonate |
6-fluoromevalonolactone |
zr 3516 |
BRD-A12426960-001-01-6 |
CHEMBL3185156 |
4-(fluoromethyl)-4-hydroxy-2-oxanone |
Q27215723 |
J-017007 |
CS-0135985 |
HY-133957 |
Class | Description |
---|---|
delta-lactone | A lactone having a six-membered lactone ring. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 1.0000 | 0.0032 | 45.4673 | 12,589.2998 | AID2517 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (22.22) | 18.7374 |
1990's | 6 (66.67) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (11.11) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.27) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |